JS006
JS006 is a humanized IgG4κ monoclonal antibody inhibitor targeting TIGIT/CD155. JS006 can be used to study advanced and/or metastatic cancers with resistance to PD-1/PD-L1 inhibitor such as non-small cell lung cancer (NSCLC), advanced lymphoma and advanced/metastatic triple negative breast cancer (TNBC) [1][2].
Product Specifications
UNSPSC
12352203
Target
Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
References & Citations
[1]Andrew B, et al. Improved treatments for advanced/metastatic cancers with checkpoint inhibitor resistance or resistance susceptibility. WO2023034336A2. 2023-03-09. |[2]JS006.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
![Human B-Cell Lymphoma Cells [SU-DHL-6]](https://cdn.genprice.uk/genprice/uk/genprice2.webp)
